You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 0.0% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -35.9 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 0.0 | 0.0 |
| Price / Book value | 18.1 |
| Latest | Forecast | |
|---|---|---|
| Revenue | n/a | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | -17.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-06-30 | n/a | -1.72 | -2.50p | -16.0 | 0.0 | n/a | n/a | 0.0% |
| 2019-06-30 | n/a | -1.68 | -2.50p | -8.7 | 0.0 | n/a | n/a | 0.0% |
| 2020-06-30 | 0.05 | -1.12 | -1.50p | -17.5 | 0.0 | n/a | n/a | 0.0% |
| 2021-06-30 | n/a | -1.72 | -2.30p | -125.0 | 0.0 | n/a | n/a | 0.0% |
| 2022-06-30 | n/a | -2.58 | -3.20p | -63.3 | 0.0 | n/a | n/a | 0.0% |
| Sareum gets approval for phase one psoriasis studies in Australia Sharecast News | 05 May |
|---|---|
| Sareum looks at options as GSK division returns cancer drug candidate Sharecast News | 06 Mar |
| Sareum confident despite recent setbacks Sharecast News | 16 Dec |
| Phase 1a clinical trial for SDC-1801 | 18-May-23 14:38 |
|---|---|
| Approval to initiate Phase 1 clinical trial | 05-May-23 17:30 |
| Half-Year Report | 22-Mar-23 14:38 |
| Update on SDC-1801 | 15-Mar-23 15:04 |
| Notice of Half-Year Results | 15-Mar-23 15:02 |